# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lili Boulanger (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET025-SYN-TD
- Date: 1915-01-19
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odile Marchetti-Rowe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- Four months of cramping pain low on the right of the abdomen, loose stools up to six times a day and at night, evening fevers, and weight loss **S**
- Has been unwell, on and off, since childhood and wants a clear answer and a plan that lets her keep composing and performing **S**

## Your goals

- Reach a diagnosis, with tuberculosis excluded, within two weeks. Target: 1915-01-28. Recorded outcome: Ileocolonoscopy, biopsies, MR enterography, interferon-gamma release assay, and chest X-ray completed in nine days; Crohn disease diagnosed and intestinal tuberculosis made very unlikely, with the mycobacterial culture still pending. **S**
- Steroid-free clinical remission by week 12 to 16 of treatment. Target: 1915-04-27. Recorded outcome: Harvey-Bradshaw Index 2 at week 12, five weeks after the prednisone taper ended. **S**
- Normal CRP and fecal calprotectin by six months, and endoscopic response at six to twelve months. Target: 1915-10-05. Recorded outcome: CRP 2 mg/L and calprotectin 42 ug/g at six months; SES-CD 14 to 2 at eight months. **S**
- Regain weight to a BMI of 19 or more and correct iron and vitamin D. Target: 1915-08-03. Recorded outcome: Weight 50.6 kg (BMI 19.8); hemoglobin 13.1, ferritin 72, vitamin D 34. **S**
- Perform her March concert and keep composing through treatment. Target: 1915-04-27. Recorded outcome: Composing most mornings; the concert went ahead in late March with a plan for bathroom access. **S**

## What we agreed to do

- Workup for suspected inflammatory bowel disease: blood count, CRP, albumin, iron studies, vitamin B12 and D, fecal calprotectin, stool tests for Clostridioides difficile and enteric pathogens, celiac serology, a pregnancy test, ileocolonoscopy with biopsies, and MR enterography. Guideline: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019 (2019) **S**
- Exclude intestinal tuberculosis before any steroid or immunosuppressive drug: interferon-gamma release assay, chest X-ray, and ileal and colonic biopsies for acid-fast stain, TB PCR, and mycobacterial culture; with hepatitis B, hepatitis C, HIV, measles, and varicella serology before treatment. Guideline: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026) **S**
- Gastroenterology (inflammatory bowel disease) consultation once the endoscopy and imaging are done, to confirm the diagnosis and choose treatment with her. Guideline: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021 (2021) **S**
- Nutrition: dietitian assessment, small frequent meals with oral nutritional supplements, and weight at every visit. Guideline: ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025) **S**
- Mood, anxiety, and work: PHQ-9 and GAD-7 at intervals, IBD psychology if needed, and a practical plan for composing and performing during treatment. Guideline: ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025) **S**
- Risankizumab 600 mg intravenously at weeks 0, 4, and 8, then 360 mg subcutaneously every 8 weeks, chosen with her as early advanced therapy; liver enzymes and bilirubin at baseline and through at least week 12; a short prednisone bridge tapered over eight weeks; no live vaccines. Guideline: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021 (2021); ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026) **S**
- Vaccines before immunosuppression: PCV20, recombinant zoster vaccine in two doses, a hepatitis B booster with an antibody check one to two months later, and influenza and COVID-19 vaccines each season; live vaccines not needed because she is immune to measles and varicella. Guideline: ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); Adult Immunization Schedule by Medical Condition and Other Indication (2026) **S**
- Iron, vitamin D, and bone: one intravenous ferric derisomaltose infusion, vitamin D3 daily, calcium while on prednisone, baseline DXA, and weight-bearing exercise. Guideline: ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025) **S**
- Treat to target: symptoms and CRP at every visit, fecal calprotectin at about three and six months, and ileocolonoscopy at six to twelve months. Guideline: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the IOIBD. Gastroenterology 2021;160:1570-1583 (2021) **S**
- Contraception, fertility, and pregnancy planning: effective contraception while the disease is active; plan pregnancy after three to six months of steroid-free remission, with a preconception review; continue the biologic in pregnancy after discussing the limited data for risankizumab; folic acid before conception. Guideline: Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2025;23:S1-S60 (2025); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026) **S**

## Follow-up

- 1915-01-19: Primary care visit for four months of abdominal pain, diarrhea, fevers, and weight loss **S**
- 1915-01-28: Diagnosis of Crohn disease with intestinal tuberculosis excluded; inflammatory bowel disease consultation the same day **S**
- 1915-03-02: Review at week 4 of risankizumab, on the day of the second induction infusion **S**
- 1915-04-27: Review at week 12, the first maintenance dose of risankizumab **S**
- 1915-08-03: Six-month review on maintenance risankizumab **S**
- 1915-10-19: Adult preventive visit **S**

This teaching document does not replace care from a qualified clinician.
